CFO Joshua Pinto sold 84,307 shares (35.3% of holdings) at $11.67 avg; NMRA unprofitable with -$58.7M net income
Joshua Pinto, CFO of Neumora Therapeutics, executed 3 separate sales totaling 84,307 shares for $984,061.15 over three trading days (August 22-26), reducing his holdings by 35.3% from 238,965 shares to 154,658 shares. The transactions occurred at prices ($11.63, $11.59, $11.78) very close to the current price of $11.71 and near the 90-day uptick of +23.1%, yet well below the 52-week high of $19.76. The sale by the CFO is material in scale, but its signal is complicated: the company is unprofitable (net income of -$58.7M in the most recent full fiscal year), which might ordinarily suggest leadership concern; however, without information on whether this sale was discretionary or scheduled under a pre-established plan, the narrative remains descriptive rather than explanatory of intent.